Your browser doesn't support javascript.
loading
Antitumor activity of the bioreductive prodrug 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) on MDA-MB-231 cells: in vitro and in vivo.
Duan, Xiao-Chuan; Yao, Xin; Zhang, Shuang; Xu, Mei-Qi; Hao, Yan-Li; Li, Zhan-Tao; Zheng, Xiu-Chai; Liu, Man; Li, Zhuo-Yue; Li, Hui; Wang, Jing-Ru; Feng, Zhen-Han; Zhang, Xuan.
Afiliação
  • Duan XC; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China, xuanzhang@bjmu.edu.cn.
  • Yao X; Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China, xuanzhang@bjmu.edu.cn.
  • Zhang S; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China, xuanzhang@bjmu.edu.cn.
  • Xu MQ; Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China, xuanzhang@bjmu.edu.cn.
  • Hao YL; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China, xuanzhang@bjmu.edu.cn.
  • Li ZT; Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China, xuanzhang@bjmu.edu.cn.
  • Zheng XC; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China, xuanzhang@bjmu.edu.cn.
  • Liu M; Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China, xuanzhang@bjmu.edu.cn.
  • Li ZY; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China, xuanzhang@bjmu.edu.cn.
  • Li H; Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China, xuanzhang@bjmu.edu.cn.
  • Wang JR; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China, xuanzhang@bjmu.edu.cn.
  • Feng ZH; Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China, xuanzhang@bjmu.edu.cn.
  • Zhang X; Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China, xuanzhang@bjmu.edu.cn.
Int J Nanomedicine ; 14: 195-204, 2019.
Article em En | MEDLINE | ID: mdl-30636872
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fenilpropionatos / Neoplasias da Mama / Pró-Fármacos / Paclitaxel / Proliferação de Células / Nanopartículas Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fenilpropionatos / Neoplasias da Mama / Pró-Fármacos / Paclitaxel / Proliferação de Células / Nanopartículas Idioma: En Ano de publicação: 2019 Tipo de documento: Article